ASTCT Talks

In this episode of ASTCT Talks, Dr. Andrés Gómez De León, physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Dr. Perla Colunga, who is one of the specialist physicians in the hematology service of UANL, discuss their paper “Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible,” which was published in the Transplantation and Cellular Therapy journal in December.

In this episode of ASTCT Talks, we’re joined by Steven Pavletic, MD, MS, Senior Clinician, Immune Deficiency Cellular Therapy Program, National Cancer Institute Center for Cancer Research; and Kirk Schultz, MD, Professor, University of British Columbia BC Children’s Hospital. Our conversation spans all-things chronic GVHD, including the latest research and discussions coming out the Chronic GVHD Consensus Conference, held in November 2020.

In this episode of ASTCT Talks, we sit down with Parameswaran Hari, MD, MCRP to discuss the role of minimal residual disease in multiple myeloma. Hari, the Armand J. Quick/William F. Stapp Professor of Hematology and the Chief of the Division of Hematology/Oncology at the Medical College of Wisconsin, said advances in MRD testing signals improvement in progression-free survival in multiple myeloma. While this is good news for clinicians, there’s still a ways to go to ensure MRD testing is being understood correctly. 

On this episode of ASTCT Talks, we sit down with Dilan Patel, MD, advanced BMT fellow at Washington University School of Medicine in St. Louis. Patel was the lead author on a paper that explored minimal residual disease negativity and lenalidomide maintenance therapy, and how those were associated with superior survival outcomes for patients with multiple myeloma.

In this episode of ASTCT Talks, we sit down with Dr. Lia Gore, professor of pediatrics in hematology-oncology and bone marrow transplantation and co-director of the Developmental Therapeutics Program at the University of Colorado Cancer Center. Dr. Gore was the co-investigator on the AALL1331 trial and led the preceding open-label Phase 1–2 trial, AALL1121, which was the first to demonstrate the antileukemic activity of single-agent blinatumomab in children with relapsed or refractory B-ALL. We talk about her research and how the trial signals future research of bispecifics in pediatric care.